Drugs / BR1019C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06220773 | May 2024 → Apr 2025 | essential hypertension, type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1019C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06220773 ↗ |